Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies

Samer Al HadidiDepartment of Hematology and Oncology, The Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX, USACorrespondence[email protected]
View further author information

Carlos Almeida RamosDepartment of Hematology and Oncology, The Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX, USAView further author information

Click to increase image sizeClick to decrease image size

Acknowledgments

Part of this manuscript was presented at the American Society of Hematology 2020 Annual meeting.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Table 1. Frequencies of analyzed clinical trials.

Download CSV Display Table

Additional information

Funding

Samer Al Hadidi reports salary support by National Heart, Lung, and Blood Institute grant No. 5T32HL092332-18.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies

Table 1. Frequencies of analyzed clinical trials.

Information for

Open access

Opportunities

Help and information

Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies

Acknowledgments

Disclosure statement

Table 1. Frequencies of analyzed clinical trials.

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature